Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).
J. Lee
No relevant relationships to disclose
C. M. Annunziata
No relevant relationships to disclose
L. M. Minasian
No relevant relationships to disclose
J. Zujewski
No relevant relationships to disclose
S. A. Prindiville
No relevant relationships to disclose
H. L. Kotz
No relevant relationships to disclose
J. Squires
No relevant relationships to disclose
N. D. Houston
No relevant relationships to disclose
J. J. Ji
No relevant relationships to disclose
M. Yu
No relevant relationships to disclose
J. H. Doroshow
No relevant relationships to disclose
E. C. Kohn
No relevant relationships to disclose